List of Excipients in Branded Drug PROPOFOL

Generic Drugs Containing PROPOFOL

Company	Ingredient	NDC	Excipient
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	EDETATE DISODIUM
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	EGG PHOSPHOLIPIDS
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	GLYCERIN
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	SOYBEAN OIL

What are the Most Frequently-Used Excipients in PROPOFOL?

# Of NDCs	Excipient
7	BENZYL ALCOHOL
6	EDETATE DISODIUM
2	EDETATE DISODIUM ANHYDROUS
20	EGG PHOSPHOLIPIDS
20	GLYCERIN

Propofol Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Propofol is a mature, high-volume injectable anesthetic whose commercial value is concentrated in formulation performance, manufacturing reliability, packaging, and hospital economics rather than active-ingredient exclusivity. The reference product, Diprivan, uses a soybean-oil lipid emulsion containing egg lecithin, glycerol, and edetate disodium. Generic products use closely related excipient systems. The strongest opportunities are differentiated ready-to-use presentations, improved emulsion stability, lower injection pain, reduced microbial risk, allergy-positioned formulations, and supply-chain resilience.

What excipients are used in propofol injectable emulsions?

The standard propofol formulation is an oil-in-water emulsion. Propofol is practically insoluble in water, so the formulation dissolves the drug in a lipid phase and disperses that phase through an aqueous vehicle.

Formulation component	Typical function	Commercial relevance
Propofol	Active pharmaceutical ingredient	Requires uniform distribution and dose accuracy
Soybean oil	Lipid vehicle and solvent	Controls drug solubilization, emulsion structure, and caloric load
Egg lecithin	Emulsifier	Stabilizes oil droplets and controls interfacial properties
Glycerol	Tonicity agent	Supports physiological osmolality
Edetate disodium, or EDTA	Chelating agent and antimicrobial-support excipient	Improves product protection against metal-catalyzed degradation and microbial proliferation
Sodium hydroxide or hydrochloric acid	pH adjustment	Maintains emulsion stability and injectability
Water for injection	Continuous phase	Sterile aqueous vehicle

The U.S. Diprivan label identifies soybean oil, glycerol, egg lecithin, and edetate disodium as formulation components. The product contains 10 mg/mL propofol and is supplied as a sterile injectable emulsion for intravenous use (FDA, 2019).

Some generic products use EDTA, while other formulations have used sulfite-based antimicrobial systems or different preservative approaches in certain markets. The excipient profile is therefore product-specific and must be assessed against the relevant label, inactive-ingredient listing, and jurisdictional approval record.

How does the Diprivan formulation compare with generic propofol?

U.S. generic propofol injectable emulsions are generally therapeutically equivalent to the reference product when approved through the ANDA pathway. The main formulation architecture remains a lipid emulsion with an emulsifier, tonicity agent, pH adjustment, and water for injection.

Attribute	Diprivan	Generic propofol injectable emulsion
Active strength	Commonly 10 mg/mL	Commonly 10 mg/mL
Dosage form	Intravenous emulsion	Intravenous emulsion
Lipid vehicle	Soybean oil	Usually soybean oil or a closely related lipid system
Emulsifier	Egg lecithin	Usually egg lecithin
Tonicity agent	Glycerol	Usually glycerol
Antimicrobial-support system	Edetate disodium in U.S. Diprivan	Product-dependent
Primary differentiation	Brand supply, presentation, labeling, device integration	Price, availability, packaging, and contracting
Regulatory route	NDA	ANDA or, for materially different products, NDA

Generic competition limits the opportunity to charge a premium for the same 10 mg/mL emulsion in a conventional vial. Commercial differentiation must usually come from presentation, logistics, safety attributes, or a materially improved formulation.

What formulation problems create commercial opportunities for propofol?

Can a new excipient system reduce pain on injection?

Pain on injection is a recognized limitation of propofol. The effect is associated with the aqueous phase, formulation pH, free propofol concentration, injection site, and administration technique. Clinical practice often uses lidocaine before or with propofol, but a manufacturer-controlled formulation that reduces pain without requiring bedside admixture could have commercial value.

Potential strategies include:

• Reducing the concentration of free propofol in the aqueous phase.
• Controlling droplet size and interfacial chemistry.
• Adjusting pH within the clinically acceptable stability range.
• Using alternative lipid blends.
• Incorporating a validated local-anesthetic strategy into the finished product.
• Developing a presentation with a separate, integrated pain-reduction component.

A new formulation would need to demonstrate equivalent anesthetic performance, emulsion integrity, injection compatibility, preservative effectiveness, extractables and leachables control, and a clinically meaningful reduction in injection pain.

Can lipid excipients improve stability and tolerability?

Soybean oil is effective but creates several constraints. It contributes a lipid load, requires control of oxidation, and forms part of the product’s allergy labeling. Alternative lipid vehicles could include medium-chain triglycerides, long-chain triglycerides from different sources, or mixed-oil systems.

The commercial objective would not be a simple substitution. A replacement lipid would need to preserve:

• Propofol solubility.
• Droplet-size distribution.
• Zeta potential and physical stability.
• Sterilization compatibility.
• Oxidative stability.
• Syringe and infusion-line compatibility.
• Pharmacokinetic comparability.
• Container closure performance.

Mixed medium-chain and long-chain triglyceride emulsions are technically plausible, but their approval would likely require more extensive pharmaceutical development than a conventional generic formulation. The formulation may be treated as a complex product rather than a routine excipient substitution if the change affects pharmacokinetics, safety, or clinical performance.

Can excipients reduce microbial risk?

Propofol emulsions can support microbial growth if handled improperly. The lipid vehicle, aseptic filling requirements, vial access, infusion duration, and post-opening storage instructions are central to product risk.

Edetate disodium is used in some products to support antimicrobial protection, but it is not a substitute for sterile manufacturing or appropriate handling. Commercial opportunities include:

• Single-dose prefilled syringes.
• Closed-system transfer devices.
• Smaller-volume presentations that reduce vial reuse.
• Packaging that minimizes repeated access.
• Formulations with validated antimicrobial-support systems.
• Improved labeling and workflow controls for anesthesia departments.

A preservative or antimicrobial-support excipient can create regulatory value only if it improves the product’s validated microbial-control profile without causing toxicity, compatibility, or infusion-related problems.

What formulations are protected by propofol patents?

The original propofol active-ingredient and conventional formulation patent estate is effectively expired in the United States and other major markets. Propofol has been commercially available as a generic injectable anesthetic for decades, and the reference product does not retain meaningful U.S. market exclusivity based on the active ingredient.

Current patent value is more likely to arise from:

• Novel lipid compositions.
• Specific droplet-size distributions.
• Preservative systems.
• Prefilled syringe architecture.
• Closed-transfer packaging.
• Stabilized concentrated formulations.
• Premixed propofol-lidocaine products.
• New delivery devices.
• Manufacturing processes that improve emulsion uniformity or shelf life.
• Formulations designed for a defined patient population.

A formulation patent must distinguish over the extensive prior art covering propofol emulsions, lipid emulsions, injectable anesthetics, and standard excipients. Broad claims covering soybean oil, egg lecithin, glycerol, and propofol are unlikely to provide strong protection in the United States.

When does propofol lose exclusivity?

Propofol lost practical market exclusivity long ago. The reference U.S. product, Diprivan, was approved under NDA 019627, and generic propofol products are listed in FDA approval records. The active ingredient has no current U.S. New Chemical Entity exclusivity, and conventional propofol injectable emulsion products do not depend on a live core patent for market protection (FDA, n.d.-a; FDA, n.d.-b).

Exclusivity category	Current commercial position
Active-ingredient patent	Expired
New Chemical Entity exclusivity	Expired
Conventional injectable-emulsion protection	No meaningful remaining core exclusivity
Orphan-drug exclusivity	Not a principal propofol market barrier
Pediatric exclusivity	Not a principal current barrier
Formulation patents	Possible for newly differentiated products
Device or packaging patents	Possible, depending on claim scope and enforcement

What is the Orange Book status of propofol?

Propofol is represented in FDA product and therapeutic-equivalence records through approved reference and generic injectable products. Orange Book relevance is primarily product-specific: the listed dosage form, strength, route, reference standard, and therapeutic-equivalence code determine generic substitution status.

For a conventional 10 mg/mL injectable emulsion, the commercial question is usually whether the product is approved as therapeutically equivalent to the relevant reference product. A materially different formulation, device, concentration, or delivery system may require a separate NDA rather than a straightforward ANDA.

Orange Book review should be paired with:

• FDA Drugs@FDA records.
• FDA approved drug labeling.
• FDA Inactive Ingredient Database entries.
• Drug shortage records.
• Product-specific ANDA information.
• State substitution rules and hospital formulary policies.

Are there Paragraph IV challenges for propofol?

Paragraph IV litigation is not a central current risk for conventional propofol injectable emulsions because the principal active-ingredient and reference-product exclusivity barriers have expired. A Paragraph IV filing could become relevant if a company obtains an approved, unexpired patent covering a new propofol formulation, delivery device, or manufacturing process.

The likely litigation targets would be:

1. A novel emulsion composition.
2. A prefilled syringe or closed-system presentation.
3. A formulation with a proprietary antimicrobial system.
4. A specific method of reducing injection pain.
5. A concentrated or reduced-volume formulation.
6. A combination product containing propofol and another active ingredient.

In such cases, the strength of the patent estate would depend on claim construction, written description, enablement, unexpected results, and whether the accused generic practices every limitation of the asserted claims.

How strong is the propofol patent estate?

The conventional propofol patent estate is weak because the basic product architecture is old, widely disclosed, and commercially standardized. A new entrant would obtain stronger protection by combining composition claims with process, packaging, and use claims.

Patent category	Relative strength for a new entrant
Propofol alone	Very weak
Propofol in soybean oil and egg lecithin	Very weak
Alternative lipid blend	Moderate if technically differentiated
Defined droplet-size profile	Moderate, but vulnerable to invalidity and infringement disputes
Preservative or antimicrobial system	Moderate
Prefilled syringe or closed transfer system	Moderate to strong if device-specific
Reduced-pain formulation	Moderate if supported by clinical data
Manufacturing process	Moderate where process parameters are difficult to design around
Broad method-of-use claims	Limited because propofol uses are well established

The best protection is likely a layered estate combining composition claims, manufacturing claims, container-closure claims, and device claims. Method-of-use patents alone are unlikely to provide durable protection for routine induction or maintenance of anesthesia.

What FDA regulatory pathway applies to new propofol formulations?

A conventional generic propofol emulsion may qualify for ANDA approval if it matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics. A formulation with a new excipient, different lipid phase, altered pharmacokinetics, new delivery device, or clinically meaningful therapeutic distinction may require an NDA.

Key development requirements include:

• Sterility and bacterial endotoxin control.
• Droplet-size distribution and globule-size limits.
• Assay and content uniformity.
• Emulsion physical stability.
• Oxidative degradation control.
• Preservative effectiveness, where applicable.
• Container-closure integrity.
• In-use stability.
• Compatibility with infusion systems.
• Extractables and leachables.
• Pharmacokinetic comparability.
• Local tolerance and injection-site safety.
• Clinical evaluation of pain or other claimed benefits.

Propofol is a complex injectable product because small changes in excipient grade, mixing energy, homogenization, sterilization, or container interaction can alter product performance.

What excipient suppliers and manufacturers have the best commercial opportunities?

Specialty excipient suppliers

The strongest supplier opportunities are in high-purity, pharmaceutical-grade materials with reliable global supply:

• Egg lecithin with controlled phospholipid composition.
• Low-peroxide soybean oil.
• Pharmaceutical-grade medium-chain triglycerides.
• Antioxidant-compatible lipid systems.
• High-purity glycerol.
• Edetate disodium and alternative chelating systems.
• Emulsion stabilizers and process aids.
• Low-binding syringe and vial materials.

The opportunity is greatest where the supplier can provide formulation support, regulatory documentation, and multi-site supply rather than only commodity excipient pricing.

Finished-dose manufacturers

Manufacturers can create value through:

• Ready-to-use prefilled syringes.
• Single-dose vials in anesthesia-specific sizes.
• Improved supply continuity.
• Regional manufacturing redundancy.
• Lower-overfill products.
• Barcode-enabled packaging.
• Closed-system presentations.
• Products optimized for automated anesthesia workflows.
• Formulations with validated lower injection pain.
• Products designed for reduced waste and shorter preparation time.

Hospital buyers typically evaluate propofol on acquisition cost, shortage risk, handling, waste, pharmacy workload, anesthesia workflow, and product reliability. A premium product must produce measurable operational savings or solve a documented supply or safety problem.

How does propofol compare with fospropofol?

Fospropofol is a water-soluble phosphate prodrug of propofol and is not an excipient-based reformulation of propofol injectable emulsion. It was developed to avoid some limitations of the lipid emulsion, but its clinical profile, onset, dosing, and commercial positioning differ.

Attribute	Propofol injectable emulsion	Fospropofol
Chemical form	Propofol	Water-soluble prodrug
Lipid emulsion required	Yes, for conventional products	No
Main formulation challenge	Emulsion stability and microbial control	Prodrug conversion and pharmacokinetics
Generic competition	Extensive	More limited, depending on market
Excipient opportunity	High within emulsion and device systems	Focused on aqueous injectable formulation and delivery
Commercial positioning	General anesthesia and procedural sedation	Specific sedation applications

Fospropofol does not eliminate the need for a differentiated propofol formulation strategy, but it creates a separate competitive benchmark for lipid-free delivery.

What generic launch scenarios exist for a new propofol product?

Low-cost conventional generic

This is the fastest route but has the weakest margin profile. The product competes primarily on manufacturing cost, supply reliability, and contracts. Excipient differentiation is limited.

Premium prefilled syringe

A prefilled syringe can reduce pharmacy preparation, dosing errors, vial waste, and handling time. The commercial case depends on device cost, stability, and hospital workflow adoption.

Low-pain formulation

This product requires controlled clinical evidence. It could command a premium in procedural sedation and high-throughput operating-room settings if it reduces the need for lidocaine pretreatment or improves patient experience.

Lipid-reduced or alternative-lipid formulation

This approach may address caloric load, lipid intolerance, oxidation, or allergy-labeling concerns. It carries greater regulatory and development risk because the formulation may no longer be a simple generic equivalent.

Supply-secure regional product

A manufacturer with redundant API, excipient, and fill-finish capacity can compete even without formulation innovation. Hospital systems may value continuity where propofol shortages disrupt surgery schedules.

What is the geographic commercial opportunity?

The United States, Europe, Japan, China, India, and large hospital markets in Latin America all have established propofol demand, but regulatory and formulation requirements differ.

• The United States rewards ANDA efficiency, shortage resilience, and hospital contracting.
• Europe places greater emphasis on centralized or national authorization, pharmacopoeial compliance, and procurement tenders.
• China and India offer manufacturing and export opportunities but face intense price competition.
• Emerging markets may favor stable, lower-cost vials over premium device presentations.
• Markets with limited cold-chain infrastructure may favor robust room-temperature stability and simplified packaging.

A global excipient strategy should use pharmacopeial-grade materials accepted across the target jurisdictions. Egg and soy labeling, preservative requirements, container standards, and allowable excipients can vary by market.

What revenue exposure does propofol create for manufacturers?

Propofol is generally a high-volume, low-to-moderate unit-price injectable. Revenue exposure is driven more by volume and contract position than by patent pricing.

Major financial risks include:

• Hospital tender price compression.
• Manufacturing interruption.
• Sterile-facility capacity constraints.
• Shortages of egg lecithin or pharmaceutical lipid materials.
• Batch rejection caused by emulsion instability.
• Product recalls linked to sterility or particulate contamination.
• Excessive packaging costs for prefilled syringes.
• Failure to secure formulary placement.
• Inability to support multiple vial and syringe configurations.

A differentiated product can improve gross margin, but the manufacturer must quantify the cost of clinical development, device validation, stability studies, specialized filling equipment, and regulatory review.

Key Takeaways

• Propofol’s conventional active-ingredient and formulation exclusivity has expired.
• The standard product uses a lipid emulsion built around soybean oil, egg lecithin, glycerol, water for injection, pH adjusters, and, in some products, EDTA.
• Commodity generic propofol has limited pricing power.
• The strongest commercial opportunities are prefilled syringes, closed-system packaging, lower-pain formulations, improved microbial-control systems, and supply-secure manufacturing.
• Alternative lipid systems may provide differentiation but can trigger a more demanding NDA-level development pathway.
• Broad patents on conventional propofol emulsions are unlikely to be strong. New value is more likely in narrow composition, process, packaging, and device claims.
• Hospital procurement rewards reliability, low waste, workflow efficiency, and shortage resilience.
• Fospropofol is a separate prodrug competitor, not a conventional excipient reformulation of propofol.

FAQs

Can propofol be formulated without soybean oil?

Yes, alternative lipid systems are technically possible, including mixed triglyceride systems, but they require proof of equivalent drug performance, emulsion stability, safety, and regulatory acceptability.

Does egg lecithin create a contraindication for patients with egg allergy?

Product labeling must control the regulatory position. Clinical allergy guidance has questioned whether ordinary egg allergy predicts propofol reactions, but the approved label and institutional policy remain controlling for product use.

Is EDTA essential in every propofol formulation?

No. EDTA is used in some products as a chelating and antimicrobial-support excipient. Its necessity depends on the formulation, container, microbial-control strategy, and regulatory specifications.

Can lidocaine be patented in a propofol product?

A propofol-lidocaine composition or administration system may support patent claims if it contains a novel, non-obvious formulation or delivery arrangement with adequate supporting data. Routine bedside coadministration is unlikely to create strong composition protection.

Are propofol prefilled syringes commercially attractive?

Yes, particularly in operating rooms and procedural-sedation centers where reduced preparation time, lower waste, and standardized dosing can offset the higher packaging cost. The commercial case depends on device stability, compatibility, and hospital procurement economics.

References

1. U.S. Food and Drug Administration. (2019). Diprivan (propofol injectable emulsion) prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs database. FDA.

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.-c). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (n.d.-d). Drug shortages database. FDA.

6. Baker, M. T., & Naguib, M. (2005). Propofol: The challenges of formulation. Anesthesiology, 103(4), 860-876.

7. McKeage, K., & Perry, C. M. (2003). Propofol: A review of its use in intensive care sedation of adults. CNS Drugs, 17(4), 235-272.

8. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP.